Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OMS103HP · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| OMS103HP irrigation solution | EXPERIMENTAL | Drug |
| vehicle irrigation solution | PLACEBO_COMPARATOR | Vehicle |
| 1 | EXPERIMENTAL | OMS103 Irrigation Solution |
| 2 | PLACEBO_COMPARATOR | Balanced Salt Solution (BSS) |
| Drug | EXPERIMENTAL | - |
| Vehicle | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| OMS103HP | DRUG | Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours |
| Vehicle | DRUG | Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours |
Inclusion Criteria: * 15 - 65 years of age * In good general health with an ACL tear that occurred from 2 weeks to 18 months prior to the day of arthroscopic surgery * Undergoing primary unilateral ACL reconstruction using a medial hamstring (semitendinosus and gracilis) autograft * Able to partici...
OMS103HP is an investigational small molecule being studied for use in anterior cruciate ligament reconstruction, knee injuries, and postoperative pain. It is administered as an irrigation solution during knee surgery. The drug is developed by Omeros Corporation and is currently in Phase 3 clinical development.
OMS103HP is a small molecule that targets multiple pathways involved in inflammation and pain. It is designed to be used as an irrigation solution during knee surgeries to reduce postoperative pain and improve recovery. The drug is being studied in patients undergoing ACL reconstruction and meniscectomy procedures.
OMS103HP is developed by Omeros Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol OMER. The company is conducting clinical trials to evaluate the safety and efficacy of OMS103HP for knee surgery-related indications.
OMS103HP is in Phase 3 clinical development. It has completed multiple Phase 3 trials in patients undergoing anterior cruciate ligament reconstruction, including both allograft and autograft procedures. The drug is investigational and has not been approved by regulatory authorities.
OMS103HP has completed several clinical trials, including NCT00226759 and NCT00226772, which were Phase 3 studies in patients undergoing allograft and autograft ACL reconstruction, respectively. Another Phase 3 trial, NCT00245271, evaluated safety in ACL reconstruction patients. A Phase 2 trial, NCT00624845, studied the drug in meniscectomy patients.
OMS103HP is a unique investigational drug developed by Omeros Corporation. It is not known to be the same as any other approved medication. The drug is being studied specifically as an irrigation solution for use during knee surgeries to address postoperative pain and inflammation.